ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • research methods and treatment
  • Reserve capacity
  • resident
  • resident memory T cell
  • resilience
  • resiliency
  • resiliency and rheumatoid arthritis (RA)
  • resiliency and self-management
  • resistin
  • resolution of disease and rheumatoid arthritis (RA)
  • resolution of disease and synovial fluid
  • resolution of disease and systemic sclerosis
  • Respiratory
  • Respiratory disease
  • respiratory disease and rheumatoid arthritis (RA)
  • respiratory disease and systemic sclerosis
  • respiratory disease and vasculitis
  • respiratory failure
  • Response Criteria
  • resting energy expenditure
  • Results
  • Resveratrol and scleroderma
  • resveratrol and synovial cells
  • Retinopathy
  • retinopathy and bull’s eye maculopathy
  • retinopathy and pediatrics
  • Retroperitoneal Fibrosing
  • Retroperitoneal Fibrosing and cancer
  • Retroperitoneal Fibrosing and fibrosis
  • Retroperitoneal Fibrosing and malignancy
  • Retroperitoneal Fibrosing and rituximab
  • Retroperitoneal Fibrosing and sialoadenitis
  • retrospective study
  • review
  • rheumatic
  • rheumatic and musculoskeletal disease and smartphone apps
  • Rheumatic and musculoskeletal disorders
  • Rheumatic disease
  • rheumatic disease and artificial intelligence
  • rheumatic disease and auto-immunity
  • rheumatic disease and axial spondyloarthritis
  • rheumatic disease and health care cost
  • rheumatic disease and health outcome
  • rheumatic disease and prescribing trends
  • rheumatic disease and rheumatic education
  • rheumatic disease and rheumatoid arthritis
  • rheumatic disease and rheumatoid arthritis (RA)
  • rheumatic disease and risk
  • rheumatic disease and risk assessment
  • rheumatic disease and risk management
  • rheumatic disease and safety
  • rheumatic disease and sleep
  • rheumatic disease and sleep apnea
  • rheumatic disease and social media
  • rheumatic disease and socio-economic inequities
  • rheumatic disease and statins
  • rheumatic disease and steroids
  • rheumatic disease and synovial cells
  • rheumatic disease and systemic sclerosis
  • rheumatic disease and teriparatide
  • rheumatic disease and time management
  • rheumatic disease and tobacco use
  • rheumatic disease and tocilizumab
  • rheumatic disease and tolerance
  • rheumatic disease and transplantation
  • rheumatic disease and treatment
  • rheumatic disease and treatment options
  • rheumatic disease and tuberculosis
  • rheumatic disease and tumor necrosis factor (TNF)
  • rheumatic disease and ultrasound
  • rheumatic disease and utilization review
  • Rheumatic disease and vaccines
  • rheumatic disease and vasculitis
  • rheumatic disease and viruses
  • rheumatic disease and women's health
  • rheumatic disease and work
  • rheumatic disease and young adults
  • Rheumatic diseases
  • rheumatic education
  • rheumatic education and academics
  • rheumatic education and medical education
  • rheumatic education and prevention
  • rheumatic education and rheumatoid arthritis (RA)
  • rheumatic education and trainee
  • rheumatic education and treatment options
  • rheumatoid arthriris
  • rheumatoid arthritis
  • Rheumatoid arthritis (RA)
  • rheumatoid arthritis (RA) and 25-hydroxyvitamin D
  • rheumatoid arthritis (RA) and abatacept
  • rheumatoid arthritis (RA) and administrative databases
  • rheumatoid arthritis (RA) and angiogenesis
  • rheumatoid arthritis (RA) and anti-CCP antibodies
  • rheumatoid arthritis (RA) and antibiotics
  • rheumatoid arthritis (RA) and autoantibodies
  • rheumatoid arthritis (RA) and axial spondyloarthritis
  • rheumatoid arthritis (RA) and B cell targeting
  • rheumatoid arthritis (RA) and Biologic agents
  • rheumatoid arthritis (RA) and biologic drugs
  • rheumatoid arthritis (RA) and Biologics
  • rheumatoid arthritis (RA) and biomarkers
  • rheumatoid arthritis (RA) and biosimilars
  • rheumatoid arthritis (RA) and cardiovascular disease
  • rheumatoid arthritis (RA) and Clinical Response
  • rheumatoid arthritis (RA) and cognitive dysfunction
  • rheumatoid arthritis (RA) and comorbidity
  • rheumatoid arthritis (RA) and diagnosis
  • rheumatoid arthritis (RA) and disability
  • rheumatoid arthritis (RA) and Disease Activity
  • rheumatoid arthritis (RA) and diversity
  • rheumatoid arthritis (RA) and dmard
  • rheumatoid arthritis (RA) and economics
  • rheumatoid arthritis (RA) and education
  • rheumatoid arthritis (RA) and Elderly
  • rheumatoid arthritis (RA) and environmental factors
  • rheumatoid arthritis (RA) and epidemiologic methods
  • rheumatoid arthritis (RA) and epigenetics
  • rheumatoid arthritis (RA) and Etiopathogenesis
  • rheumatoid arthritis (RA) and flow cytometry
  • rheumatoid arthritis (RA) and functional status
  • rheumatoid arthritis (RA) and health care cost
  • rheumatoid arthritis (RA) and health outcome
  • rheumatoid arthritis (RA) and herbal remedies
  • rheumatoid arthritis (RA) and human leukocyte antigens (HLA)
  • rheumatoid arthritis (RA) and Imaging
  • rheumatoid arthritis (RA) and infection
  • rheumatoid arthritis (RA) and inflammation
  • rheumatoid arthritis (RA) and Janus kinase (JAK)
  • rheumatoid arthritis (RA) and magnetic resonance imaging (MRI)
  • rheumatoid arthritis (RA) and Medicare
  • rheumatoid arthritis (RA) and meta-analysis
  • rheumatoid arthritis (RA) and microbiome
  • rheumatoid arthritis (RA) and microparticles
  • rheumatoid arthritis (RA) and obesity
  • rheumatoid arthritis (RA) and osteoporosis
  • rheumatoid arthritis (RA) and outcome measures
  • rheumatoid arthritis (RA) and pathogenesis
  • rheumatoid arthritis (RA) and patient-reported outcome measures
  • rheumatoid arthritis (RA) and Pemphigus vulgaris(PV)
  • rheumatoid arthritis (RA) and Peripheral blood
  • rheumatoid arthritis (RA) and physical function
  • rheumatoid arthritis (RA) and psoriatic arthritis
  • rheumatoid arthritis (RA) and quality of care
  • rheumatoid arthritis (RA) and quality of life
  • rheumatoid arthritis (RA) and race/ethnicity
  • rheumatoid arthritis (RA) and radiography
  • rheumatoid arthritis (RA) and registry
  • rheumatoid arthritis (RA) and remission
  • rheumatoid arthritis (RA) and research methods
  • rheumatoid arthritis (RA) and rheumatoid arthritis
  • rheumatoid arthritis (RA) and rheumatologic disease
  • rheumatoid arthritis (RA) and rheumatologic practice
  • rheumatoid arthritis (RA) and risk
  • rheumatoid arthritis (RA) and risk assessment
  • rheumatoid arthritis (RA) and risk management
  • rheumatoid arthritis (RA) and rituximab
  • rheumatoid arthritis (RA) and safety
  • rheumatoid arthritis (RA) and salivary gland
  • rheumatoid arthritis (RA) and sarcoidosis
  • rheumatoid arthritis (RA) and sarcopenia
  • rheumatoid arthritis (RA) and self-management
  • rheumatoid arthritis (RA) and serologic tests
  • rheumatoid arthritis (RA) and seronegative spondyloarthropathy
  • rheumatoid arthritis (RA) and severity
  • rheumatoid arthritis (RA) and sex bias
  • rheumatoid arthritis (RA) and sex hormones
  • rheumatoid arthritis (RA) and shared dicision making
  • rheumatoid arthritis (RA) and shoulder disorders
  • rheumatoid arthritis (RA) and signal transduction
  • rheumatoid arthritis (RA) and skin
  • rheumatoid arthritis (RA) and sleep
  • Rheumatoid arthritis (RA) and sleep apnea
  • rheumatoid arthritis (RA) and sleep disorders
  • rheumatoid arthritis (RA) and small molecules
  • rheumatoid arthritis (RA) and social media
  • rheumatoid arthritis (RA) and social support
  • rheumatoid arthritis (RA) and socio-economic inequities
  • rheumatoid arthritis (RA) and socioeconomic factors
  • rheumatoid arthritis (RA) and socioeconomic status
  • rheumatoid arthritis (RA) and sonography
  • rheumatoid arthritis (RA) and spine involvement
  • rheumatoid arthritis (RA) and spondylarthritis
  • rheumatoid arthritis (RA) and spondylarthropathy
  • rheumatoid arthritis (RA) and spondyloarthitis
  • rheumatoid arthritis (RA) and Spondyloarthritis
  • rheumatoid arthritis (RA) and statin
  • rheumatoid arthritis (RA) and statins
  • rheumatoid arthritis (RA) and statistical methods
  • rheumatoid arthritis (RA) and statistics
  • rheumatoid arthritis (RA) and stem cells
  • rheumatoid arthritis (RA) and steroids
  • rheumatoid arthritis (RA) and strategic planning
  • Rheumatoid arthritis (RA) and stress
  • rheumatoid arthritis (RA) and subchondral bone
  • rheumatoid arthritis (RA) and surgery
  • rheumatoid arthritis (RA) and syk
  • rheumatoid arthritis (RA) and synovial cells
  • rheumatoid arthritis (RA) and synovial fluid
  • rheumatoid arthritis (RA) and synovitis
  • rheumatoid arthritis (RA) and synovium
  • First |
  • « Previous Page
  • 51
  • 52
  • 53
  • 54
  • 55
  • [56]
  • 57
  • 58
  • 59
  • 60
  • 61
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology